Drug Profile


Alternative Names: Bupropion/naltrexone; Contrave; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; NB32

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Orexigen Therapeutics
  • Developer Kwang Dong Pharmaceutical; Orexigen Therapeutics
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • No development reported Depressive disorders; Smoking withdrawal

Most Recent Events

  • 06 Jan 2017 Safety and efficacy results from the phase IIIb Ignite trial in Obesity released by Orexigen Therapeutics
  • 05 Jan 2017 Orexigen intends to launch naltrexone/bupropion in Spain
  • 19 Dec 2016 Naltrexone/ bupropion licensed to Biologix FZCo in Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, Bahrain, Lebanon, Jordan, Iraq and Iran for commercialisation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top